Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons

Neuroscience

Volumn 154, Issue 4, 2008, Pages 1525-1532

  Frolov, R V ^a   Slaughter, M M ^a   Singh, S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

coxibs; electrophysiology; pharmacology; potassium channels; sodium channels; voltage gated channels

Indexed keywords

CELECOXIB; SODIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ELECTROPHYSIOLOGY; ION CURRENT; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; RETINA AMACRINE CELL; RETINA BIPOLAR GANGLION CELL; RETINA NERVE CELL;

ACTION POTENTIALS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRAZOLES; RATS; RETINAL NEURONS; SODIUM CHANNELS; SULFONAMIDES;

EID: 45849112870     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.05.004     Document Type: Article

References (23)

1. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., and Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
2. Coulter D.M., Clark D.W., and Savage R.L. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 327 (2003) 1214-1215
3. Davies N.M., McLachlan A.J., Day R.O., and Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38 (2000) 225-242
4. Dogne J.M., Thiry A., Pratico D., Masereel B., and Supuran C.T. Dual carbonic anhydrase-cyclooxygenase-2 inhibitors. Curr Top Med Chem 7 (2007) 885-891
5. Feigenspan A., Gustincich S., Bean B.P., and Raviola E. Spontaneous activity of solitary dopaminergic cells of the retina. J Neurosci 18 (1998) 6776-6789
6. Flower R.J. The development of COX2 inhibitors. Nat Rev Drug Discov 2 (2003) 179-191
7. Fraunfelder F.W., Solomon J., and Mehelas T.J. Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol 124 (2006) 277-279
8. Frolov R.V., Berim I.G., and Singh S. Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J Biol Chem 283 (2008) 1518-1524
9. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., and Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
10. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 (2006) 736-747
11. Hasinoff B.B., Patel D., and Wu X. The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovasc Toxicol 7 (2007) 19-27
12. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Garner C., Seibert K., and Marnett L.J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280 (1998) 1268-1270
13. Kasten M.R., Rudy B., and Anderson M.P. Differential regulation of action potential firing in adult murine thalamocortical neurons by Kv3.2, Kv1, and SK potassium and N-type calcium channels. J Physiol 584 (2007) 565-582
14. Kern M.A., Haugg A.M., Koch A.F., Schilling T., Breuhahn K., Walczak H., Fleischer B., Trautwein C., Michalski C., Schulze-Bergkamen H., Friess H., Stremmel W., Krammer P.H., Schirmacher P., and Muller M. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66 (2006) 7059-7066
15. Luo X., Baba A., Matsuda T., and Romano C. Susceptibilities to and mechanisms of excitotoxic cell death of adult mouse inner retinal neurons in dissociated culture. Invest Ophthalmol Vis Sci 45 (2004) 4576-4582
16. Mitchell J.A., and Warner T.D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5 (2006) 75-86
17. + currents in rat dorsal root ganglion neurons. Brain Res 1148 (2007) 53-61
18. Reiff D.F., and Guenther E. Developmental changes in voltage-activated potassium currents of rat retinal ganglion cells. Neuroscience 92 (1999) 1103-1117
19. Scholz A., and Vogel W. Tetrodotoxin-resistant action potentials in dorsal root ganglion neurons are blocked by local anesthetics. Pain 89 (2000) 47-52
20. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., and Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
21. Tabata T., and Kano M. Heterogeneous intrinsic firing properties of vertebrate retinal ganglion cells. J Neurophysiol 87 (2002) 30-41
22. Weber A., Casini A., Heine A., Kuhn D., Supuran C.T., Scozzafava A., and Klebe G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47 (2004) 550-557
23. Zhang Y., Tao J., Huang H., Ding G., Cheng Y., and Sun W. Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacol Res 56 (2007) 267-274